S&P 500 7,323.63 −0.23%
Nasdaq 24,429.89 +0.42%
S&P/TSX 34,578.05 −2.09%
Apple 352.45 +0.15%
Nvidia 150.96 −2.89%
Microsoft 508.29 +0.40%
Shopify 199.78 −1.50%
Royal Bank 272.26 −3.11%
CAD/USD 0.6993 −0.01%
PRE-MKT · 05:50 ET
Market ClerkRecap
Thu Nov 19 · pre-market7 signals on Nov 18520 insider buys this week · $248.1MCIRO short report next: Nov 30The week ahead

TLSI

TriSalus Life Sciences, Inc.
NASDAQ · HEALTH CARE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
2.45
+0.15 +6.75%
USD · Nov 18, 06:40 p.m. ET

A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up

Financials

SEC XBRL · 28 PERIODS · WHOLE USD

By quarter

PeriodRevenueYoYGross marginOperating incomeNet incomeYoYEPSOp. cash flowCapexFree cash flowFiled
Q3 2026 · Sep 30$12.9M+11.3%86.2%−$7.7M−$8.9M—-0.15−$5.3M$90K−$5.4MNov 10
Q2 2026 · Jun 30$11.4M+1.7%86.8%−$9.8M−$9.2M—-0.16−$10.1M$82K−$10.2MNov 10
Q1 2026 · Mar 31$8.9M−2.9%86.2%−$8.4M$1.5M—0.03−$6.5M$141K−$6.6MNov 10
Q4 2025 · Dec 31derived$13.2M+59.8%86.7%−$3.3M−$9.8M—-0.12−$2.5M$41K−$2.5MMar 5
Q3 2025 · Sep 30$11.6M+57.4%83.5%−$9M−$10.8M—-0.96−$3.7M$216K−$3.9MNov 10
Q2 2025 · Jun 30$11.2M+52.3%83.9%−$7.3M−$8.3M—-0.27−$7.3M−$93K−$7.2MNov 10
Q1 2025 · Mar 31$9.2M+42.0%83.7%−$7.3M−$10.4M—-0.39−$4.5M$754K−$5.3MNov 10
Q4 2024 · Dec 31derived$8.3M+44.4%85.3%−$7.6M−$10.1M—-0.40−$5.7M$50K−$5.8MMar 5
Q3 2024 · Sep 30$7.3M—86.3%−$8.7M−$2.4M—-0.12−$10.8M$169K−$11MNov 13
Q2 2024 · Jun 30$7.4M—87.6%−$8.2M−$4.3M—-0.21−$13.4M$60K−$13.5MNov 13
Q1 2024 · Mar 31$6.5M—85.0%−$11.7M−$13.2M—-0.60−$10.9M$66K−$10.9MNov 13
Q4 2023 · Dec 31derived$5.7M—89.8%−$14.2M−$35.6M—-1.05−$9.2M$372K−$9.5MMay 30

By fiscal year

YearRevenueGross marginOperating incomeNet incomeNet marginEPSOp. cash flowCapexFree cash flowBuybacksDividends paid
FY2025 · to Dec 31$45.2M84.6%−$26.9M−$39.2M-86.9%-1.84−$18M$918K−$18.9M——
FY2024 · to Dec 31$29.4M86.1%−$36.2M−$30M-102.1%-1.31−$40.8M$345K−$41.2M——
FY2023 · to Dec 31$18.5M85.9%−$54.5M−$59.4M-320.7%-6.77−$50.6M$588K−$51.2M——
FY2022 · to Dec 31$12.4M81.8%−$36.4M−$47.2M-380.6%-161.55−$32.3M$655K−$33M$232.4M—
FY2021 · to Dec 31——−$3M$4.8M——−$1.7M————

Every number comes from TriSalus Life Sciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.

Watch TLSI. Know when insiders buy.
One email the day a filing lands. Free.